Omnix Medical
Novel Antibiotic Agents to Combat Resistant Bacteria
Company Overview
Snapshot
Founded in May 2015 by Moshik Cohen-Kutner and Niv Bachnoff, Omnix Medical operates with 11–50 employees. The company has raised $43.75 million across 4 funding rounds from 10 investors, with European Innovation Council and Harel Insurance & Finance leading its latest Series C round. In June 2026, Omnix Medical announced the first patients dosed in its.
Business overview
Omnix Medical is a clinical-stage biopharmaceutical company focused on developing next-generation anti-infective drugs to combat antimicrobial resistance (AMR). The company's proprietary technology mimics the innate immune system of insects, utilizing unique molecules to selectively eliminate resistant bacterial strains without toxic effects. Omnix Medical's lead compound, OMN6, is a first-in-class antimicrobial peptide designed to disrupt bacterial cell membranes, making it effective against various bacterial genotypes and resistance phenotypes. The company targets life-threatening hospital-acquired infections (HIA) caused by Gram-negative bacteria like Acinetobacter baumannii, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.
Strategic signal
In June 2026, Omnix Medical announced the dosing of the first patients in its. This milestone signals significant progress in the clinical development of a novel treatment for hospital-acquired infections, demonstrating the company's commitment to advancing its pipeline and addressing the critical challenge of drug-resistant bacteria. For investors, this indicates a positive step towards potential market validation and future commercialization in the biopharmaceutical industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Omnix Medical's core focus?
- Omnix Medical is a clinical-stage biopharmaceutical company developing next-generation anti-infective drugs to combat antimicrobial resistance, focusing on therapies resilient against resistance development.
- When did Omnix Medical begin its Phase II trial for OMN6?
- In June 2026, Omnix Medical announced that the first patients were dosed in its.
- Which investors participated in Omnix Medical's Series C funding round?
- In October 2025, Omnix Medical secured Series C funding from investors including.
- What is the mechanism of action for Omnix Medical's lead compound, OMN6?
- OMN6's mechanism of action is based on the disruption of bacterial cell membranes, making it effective regardless of bacterial genotype or resistance phenotype, and it acts as a fast-acting bactericidal agent.
- Which investors led Omnix Medical's A Round funding?
- In November 2020, Omnix Medical completed an A Round with lead investors Entrée Capital.